Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01535820 · ClinicalTrials.gov registry record · Phase 1
The Effect of an Adhesive Overlay on the Delivery of Contraceptive Hormones From ORTHO EVRA® in Healthy Women
A Phase 1 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT01535820 is a Phase 1 study that has completed, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 54 participants.
The verdict
NCT01535820, a Phase 1 study, has completed, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the bioequivalence of the contraceptive hormones of ORTHO EVRA when the patch is applied with and without an adhesive overlay.
Interventions
- DRUG Treatment A: ORTHO EVRA patch (NGMN + EE) with an adhesive overlay
- DRUG Treatment B: ORTHO EVRA patch (NGMN + EE) without an overlay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2011-03 |
| Est. Completion | 2011-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01535820
The ClinicalTrials.gov registry entry for NCT01535820 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Treatment A: ORTHO EVRA patch (NGMN + EE) with an adhesive overlay is the first listed.
NCT01535820 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01535820 about?
NCT01535820 is a clinical study titled "The Effect of an Adhesive Overlay on the Delivery of Contraceptive Hormones From ORTHO EVRA® in Healthy Women". The purpose of this study is to assess the bioequivalence of the contraceptive hormones of ORTHO EVRA when the patch is applied with and without an adhesive overlay.
What is the current status of trial NCT01535820?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2011-03. Estimated completion is 2011-07.
What interventions are being tested in trial NCT01535820?
The interventions under investigation include: Treatment A: ORTHO EVRA patch (NGMN + EE) with an adhesive overlay (DRUG), Treatment B: ORTHO EVRA patch (NGMN + EE) without an overlay (DRUG).
Who is sponsoring clinical trial NCT01535820?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.